Orlando、FLにおける転移性癌の臨床試験
Orlandoとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する29件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Orlando
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Advent Health, Orlando
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- AdventHealth Cancer Institute, Orlando
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
被験者募集中第2/3相
- AdventHealth Orlando, Orlando
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Altamonte Springs · 9マイル先
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Florida Cancer Specialists, Orlando
- Orlando Health Ambulatory Care Center, Orlando
- Orlando Health Cancer Institute, Orlando
- 他4件
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- AdventHealth Orlando, Orlando
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- AdventHealth Orlando, Orlando
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- AdventHealth Altamonte Springs, Altamonte Springs · 9マイル先
- Clermont Oncology Center, Clermont · 24マイル先
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
被験者募集中第1/2相
- Orlando Health Ambulatory Care Center, Orlando
- Orlando Health Cancer Institute, Orlando
- Orlando Health Orlando Regional Medical Center, Orlando
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Clinical Study Site, Orlando
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Orlando Health Cancer Institute, Orlando
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Orlando
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Advent Health - Orlando, Orlando
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute - Florida Cancer Specialists, Orlando
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Adventhealth, Celebration · 17マイル先
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
被験者募集中第2相
- Orlando Health, Orlando
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- Advent Health, Orlando
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Orlando
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Orlando Health UF Health Cancer Center, Orlando
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute, Orlando
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
被験者募集中第3相
- Orlando Health Cancer Institute, Orlando
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Orlando
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- AdventHealth Medical Group Oncology & Hematology at Orlando, Orlando
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Florida Cancer Specialists, Orlando
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- AdventHealth Cancer Institute, Celebration · 17マイル先
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Florida Cancer Specialists-Lake Nona, Orlando
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Florida Cancer Specialists, Orlando
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
Orlandoにおける他の研究
- 非小細胞肺癌44件の研究
- 肥満症32件の研究
- 過体重27件の研究
- アルツハイマー病25件の研究
- 2型糖尿病25件の研究
- がん（全種類）24件の研究
- 乳がん23件の研究
- 卵巣がん22件の研究
- 潰瘍性大腸炎22件の研究
- 肺がん21件の研究
- 大腸癌19件の研究
- 大うつ病性障害19件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。